Global Uveitis Treatment Market, by Treatment Type (Corticosteroids, Immunosuppressant, Monoclonal Antibodies, Cycloplegic Agents, Antibiotics, Antivirals, Antifungal, Analgesics), by Disease type (Anterior Uveitis, Posterior Uveitis, Intermediate Uveitis, Pan uveitis), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Drug Stores) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 710.0 Million in 2022 and is expected to exhibit a CAGR of 5.3% during the forecast period (2022-2030), as highlighted in a new report published by Coherent Market Insights.
The increasing adoption of organic strategies such as launch of informative websites by market players is expected to drive the global uveitis treatment market over the forecast period. For instance, on January 05, 2022, Tarsier Pharma clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics for blinding ocular diseases announced the launch of an education website about the disease uveitic glaucoma at www.uveiticglaucoma.com, as a service to the public.
Global Uveitis Treatment Market– Impact of Coronavirus (COVID-19) Pandemic
The COVID-19 pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses across all sectors, including the private healthcare sector. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry, mainly due to strict lockdown in several regions. Private healthcare is one such sector that has been impacted significantly by the COVID-19 pandemic.
However, the COVID-19 pandemic had a positive impact on the uveitis treatment market, owing to the increasing efforts by the key players in the market to develop vaccines for COVID-19 infection. For instance, in March 2020, Belgium-based Galapagos announced that the company is pausing enrollment in some clinical trials that include its Phase II and Phase III trials of filgotinib in Crohn’s disease, psoriatic arthritis and uveitis.
Global Uveitis Treatment Market: Key Developments
Major players in the market are focused on research & development of new products to expand their product portfolio which is expected to boost the market growth over forecast period. For instance, in March 2020, EyePoint Pharmaceuticals, Inc. announced positive topline 36-month follow-up data from the second Phase 3 trial of YUTIQ (fluocinolone acetonide intravitreal implant) 0.18 mg three-year micro-insert for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.
Increasing organic activity by market players is expected to drive the market growth over the forecast period. For instance, on September 20, 2022, Alimera Sciences, Inc. a biopharmaceutical company specializes in the commercialization and development of prescription ophthalmic pharmaceuticals announces that Alimera Sciences Europe Limited, its Ireland-based European subsidiary, has been granted reimbursement for ILUVIEN (fluocinolone acetonide intravitreal implant) 0.19 mg sustained release intravitreal implant for non-infectious uveitis affecting the posterior segment in Ireland. The Health Service Executive Corporate Pharmaceutical Unit and National Centre for Pharmacoeconomics in Ireland approved reimbursement in accordance with the product's label in Europe.
Browse 27 Market Data Tables and 31 Figures spread through 156 Pages and in-depth TOC on “Global Uveitis Treatment Market”- Forecast to 2030, Global Uveitis Treatment Market, by Treatment Type (Corticosteroids, Immunosuppressant, Monoclonal Antibodies, Cycloplegic Agents, Antibiotics, Antivirals, Antifungal, Analgesics), by Disease type (Anterior Uveitis, Posterior Uveitis, Intermediate Uveitis, Pan uveitis), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Drug Stores) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights prevalent in this market, click the link below:
https://www.coherentmarketinsights.com/market-insight/uveitis-treatment-market-1094
Moreover, compounds in clinical trials are expected to offer lucrative growth opportunities for players in the global uveitis treatment over the forecast period. For instance, in June 2020, Tarsius Pharma, a clinical-stage biopharmaceutical company, completed patient enrollment in the company's Phase I/II trial of TRS01 in patients with active anterior non-infectious uveitis.
Key Takeaways of the Global Uveitis Treatment Market:
- The global uveitis treatment market is expected to exhibit a CAGR of 5.3% during the forecast period due to the increasing adoption of strategies such as collaborations and partnerships by the key players. For instance, on August 19, 2021, L V Prasad Eye Institute (LVPEI), a World Health Organization (WHO) collaborating center for the prevention of blindness, has entered into a partnership with DocMode a global platform that facilitates authoritative, comprehensive and interactive online learning programs to roll out its online Continuing Medical Education (CME) initiative on uveitis. This partnership brings 12 courses; one program on anterior Uveitis, 3 program on posterior Uveitis, one program each on panuveitis, intermediate Uveitis, scleritis and episcleritis, ocular imaging in Uveitis, laboratory investigations in Uveitis and 3 programs on principles of treatment outcome.
- Among treatment type, corticosteroids segment is estimated to hold a dominant position in the global uveitis treatment market over the forecast period. Owing to its use as a first line treatment. For instance, according to an article published in Springer Nature on January 4, 2022, it is stated that the regional corticosteroid was used most frequently as the first line treatment in more than half of posterior uveitis cases.
- Among regions, North America is estimated to account for the largest market share in the global uveitis treatment market over the forecast period, owing to increasing research and development activities by market players. For instance, Aldeyra Therapeutics, which is a biotechnology company devoted to developing and commercializing next-generation medicines, one of its new development ADX-102 Ophthalmic Solution, is in Phase 2 clinical trial for the treatment of noninfectious anterior uveitis.
- Major players operating in the global uveitis treatment market include AbbVie, Novartis AG, Bausch Health Companies Inc., Galapagos NV, EyePoint Pharmaceuticals, Inc., Clearside Biomedical, Tarsier Pharma Ltd, Santen Pharmaceutical Co., Ltd., Bausch & Lomb Incorporated, Sanofi and Regeneron Pharmaceuticals, Inc., Alimera Sciences
